Jun 16, 2026 · 6 min

SpaceX subsidiary merges with Cursor in sixty billion dollar AI deal

SpaceX Agrees to Merge With Cursor; Novo to File for China Approval of Wegovy; Dave & Buster's Misses Estimates

This episode highlights the rapidly shifting dynamics in tech valuations, global pharmaceutical expansion, and the consumer headwinds currently shaping corporate earnings.

3 key takeaways

1SpaceX subsidiary SpaceX67 is merging with AI code editor Cursor in a deal implying a sixty billion dollar equity value.
2Novo Nordisk plans to seek regulatory approval for an oral version of its weight-loss drug Wegovy in China.
3Dave and Buster's stock tumbled fifteen percent following a first-quarter revenue miss blamed on soft consumer sentiment.

Don't miss

Dan Curtis breaks down the financial mechanics and market reaction behind the sixty billion dollar SpaceX and Cursor merger.

The brief

A massive $60 billion merger deal is shaking up the tech sector. SpaceX subsidiary SpaceX67 has agreed to merge with Cursor, the AI-powered software development platform, sending premarket shares up by 9 percent as investors digest the valuation.

In the pharmaceutical sector, Novo Nordisk is preparing to expand its global footprint by seeking regulatory approval for an oral version of its blockbuster weight-loss drug Wegovy in China, targeting a massive new market for GLP-1 treatments.

Meanwhile, consumer headwinds are hitting the retail sector hard. Dave & Buster's saw its stock plunge 15 percent in premarket trading after missing first-quarter revenue estimates, blaming elevated gas prices and soft consumer sentiment.

On a brighter note, chip and memory stocks are continuing their upward momentum. Giants like Western Digital, Micron, and SanDisk rallied further from record highs as easing geopolitical tensions brought relief to the semiconductor market.

What was said on this episode

8 statements · 6 positive · 2 negative

Dan Curtison Cursor mergerPositive1:08
Cursor merger implies a $60 billion equity value.
“which implies a 60 billion equity value for the company. Cursor.”
Listen at 1:08
Dan Curtison SpaceXPositive1:35
SpaceX has a $2.7 trillion premarket market capitalization.
“We're at $2.7 trillion market cap using the pre market price.”
Listen at 1:35
Dan Curtison SpaceX versus Microsoft market capitalizationPositive1:49
SpaceX could surpass Microsoft’s market capitalization if Microsoft’s value remains unchanged.
“It could pass Microsoft if Microsoft stays flat.”
Listen at 1:49
Dan Curtison Novo Nordisk GLP-1 productsPositive2:43
Novo Nordisk’s GLP-1 products accounted for 80% of sales last year.
“Those accounted for 80% of the company's sales last year.”
Listen at 2:43
Dan Curtison Novo NordiskNegative2:55
Novo Nordisk’s obesity-care unit is growing at its slowest rate since 2020.
“it's the slowest for that unit since 2020.”
Listen at 2:55
Dan Curtison Dave & Buster'sNegative3:19
Dave & Buster’s first-quarter revenue was about $560 million, below estimates.
“the company reported first quarter revenue of about $560 million which was shy of estimates”
Listen at 3:19
Dan Curtison Chip stocksPositive4:23
Receding Middle East tensions are strongly benefiting chip stocks.
“This place has seen a massive tailwind as the Middle east tensions kind of recede a bit.”
Listen at 4:23
Dan Curtison Chip stocksPositive4:33
Chip stocks are expected to reach new record highs today.
“We're looking for new record highs in the space today.”
Listen at 4:33

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Featuring

Mentioned

Listen to the full episode and explore every guest, topic, and moment on PodLume.

Listen to the full episode Or get the iOS app